Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124221 | 0.83 | CPA1 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL1402037 | 0.82 | CYP2C9 (0.58) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Hydrochloric Acid SCHEMBL3855530 | 0.81 | TDP1 (0.59) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL1908703 | 0.79 | HRH3 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL6375814 | 0.79 | CYP2C9 (0.34) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL18161622 | 0.79 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL14375521 | 0.79 | CDK5 (0.35) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL6368933 | 0.78 | CYP2C9 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL12226755 | 0.78 | CPA1 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL11477981 | 0.78 | CPA1 (0.35) | CYP2C9TSHRCYP2C19MTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020458-A1 | METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS | Seal Rock Therapeutics, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-8637557-B2 | Aminothiazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2357179-A1 | Thiazol-2-yl organic compounds | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2011048936-A1 | AMINOTHIAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2011-04-28 | — | — | WO | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | AKT3, AKT2, JAK1 | CYP2C9 2083/4885TSHR 1612/4885CYP2C19 2446/4885 |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | CYP2C9 3428/4885TSHR 4301/4885CYP2C19 3926/4885 |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | CYP2C9 3872/4885TSHR 1324/4885CYP2C19 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.